Page last updated: 2024-08-24

triazoles and MK-8353

triazoles has been researched along with MK-8353 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Adjei, AA; Bishop, WR; Carr, D; Chun, P; Cooper, A; Dayananth, P; Deng, Y; Flaherty, KT; Fong, PC; Hwu, WJ; Kirschmeier, P; Long, BJ; Miselis, NR; Moreno, BH; Moschos, SJ; Ramanathan, RK; Ribas, A; Robert, L; Rubin, EH; Rubino, J; Rush, TS; Samatar, AA; Schiller, J; Shapira-Frommer, R; Shipps, GW; Sullivan, RJ; Tawbi, HA; Zhang, D1
Gong, J; Jiang, Z; Yang, T; Zhu, Y1
Bomsztyk, K; Goryca, K; Kopczynski, M; Kulecka, M; Majewska, E; Masiejczyk, M; Mikula, M; Ostrowski, J; Pysniak, K; Pyziak, K; Rumienczyk, I; Rzymski, T; Sandowska-Markiewicz, Z; Statkiewicz, M; Wojcik-Jaszczynska, K; Wojcik-Trechcinska, U1

Trials

1 trial(s) available for triazoles and MK-8353

ArticleYear
Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
    JCI insight, 2018, 02-22, Volume: 3, Issue:4

    Topics: Administration, Oral; Adult; Animals; Biological Availability; Cell Line, Tumor; Diarrhea; Dogs; Dose-Response Relationship, Drug; Drug Eruptions; Drug Evaluation, Preclinical; Fatigue; Female; Humans; Indazoles; Male; MAP Kinase Signaling System; Maximum Tolerated Dose; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nausea; Neoplasm Staging; Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Triazoles; Xenograft Model Antitumor Assays; Young Adult

2018

Other Studies

2 other study(ies) available for triazoles and MK-8353

ArticleYear
In vitro and in vivo pharmacokinetics and metabolism of MK-8353 by liquid chromatography combined with diode array detector and Q-Exactive-Orbitrap tandem mass spectrometry.
    Journal of pharmaceutical and biomedical analysis, 2019, May-10, Volume: 168

    Topics: Administration, Intravenous; Administration, Oral; Animals; Biological Availability; Chromatography, Liquid; Dogs; Female; Humans; Indazoles; Male; Protein Kinase Inhibitors; Pyridines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Species Specificity; Tandem Mass Spectrometry; Triazoles

2019
Selective Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibition by the SCH772984 Compound Attenuates In Vitro and In Vivo Inflammatory Responses and Prolongs Survival in Murine Sepsis Models.
    International journal of molecular sciences, 2021, Sep-22, Volume: 22, Issue:19

    Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chemokine CCL2; Disease Models, Animal; Down-Regulation; Drug Repositioning; Endotoxemia; Gene Expression Regulation; Indazoles; Lipopolysaccharides; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 3; Piperazines; Platelet Activation; Pyridines; Pyrrolidines; RAW 264.7 Cells; Transcriptome; Triazoles; Tumor Necrosis Factor-alpha

2021